Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850, USA.
Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, MD 20742, USA.
Viruses. 2021 May 29;13(6):1027. doi: 10.3390/v13061027.
An effective vaccine for the hepatitis C virus (HCV) is a major unmet medical and public health need, and it requires an antigen that elicits immune responses to multiple key conserved epitopes. Decades of research have generated a number of vaccine candidates; based on these data and research through clinical development, a vaccine antigen based on the E1E2 glycoprotein complex appears to be the best choice. One bottleneck in the development of an E1E2-based vaccine is that the antigen is challenging to produce in large quantities and at high levels of purity and antigenic/functional integrity. This review describes the production and characterization of E1E2-based vaccine antigens, both membrane-associated and a novel secreted form of E1E2, with a particular emphasis on the major challenges facing the field and how those challenges can be addressed.
一种有效的丙型肝炎病毒 (HCV) 疫苗是一项重大的未满足的医学和公共卫生需求,它需要一种能够引发针对多个关键保守表位的免疫反应的抗原。几十年来的研究已经产生了许多疫苗候选物;基于这些数据和通过临床开发进行的研究,基于 E1E2 糖蛋白复合物的疫苗抗原似乎是最佳选择。基于 E1E2 的疫苗开发的一个瓶颈是抗原难以大量生产,并且难以达到高纯度和抗原/功能完整性。本综述描述了基于 E1E2 的疫苗抗原的生产和特性,包括膜相关形式和新型分泌形式的 E1E2,特别强调了该领域面临的主要挑战以及如何解决这些挑战。